24 results about "Metapneumovirus" patented technology

The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from a respiratory syncytial virus, a metapneumovirus, a human parainfluenza virus, or a combination thereof. The multisubunit nucleic acid encodes a multisubunit peptide.

The invention relates to the technical field of biology, in particular to a primer probe combination product for respiratory tract infection detection. A plurality of specific primers and self-quenching probes are integrated in a single reaction system; simultaneous, rapid and rapid detection on 15 respiratory pathogens (including influenza A virus, influenza B virus, respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, mycoplasma pneumoniae, parainfluenza virus, rhinovirus, enterovirus, coronavirus, adenovirus, metapneumovirus, bordetella pertussis, bocavirus, chlamydia pneumoniae and chlamydia psittaci) is realized. The detection is accurate.

The invention discloses a primer group and method for human metapneumovirus whole genome sequencing and application. Two groups of specific primer pools are designed for the metapneumovirus, totally comprise 21 primers, can effectively amplify the metapneumovirus type A and the metapneumovirus type B, are high in sensitivity and suitable for multi-platform detection, and provide a new direction for detection, typing, traceability and evolutionary analysis of the metapneumovirus.

This invention relates to a human monoclonal neutralizing antibody targeting the metapneumovirus F protein and its applications. It comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region includes complementary determinant regions HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively; and / or, the light chain variable region includes complementary determinant regions LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:4, AAS, and SEQ ID NO:5, respectively. The metapneumovirus monoclonal neutralizing antibody MV32 of this invention can specifically bind to the metapneumovirus F antigen (approximately 0.6 nM) and exhibits good broad-spectrum neutralizing activity against representative strains such as hMPV A1, hMPV B1, and hMPV A2b. It also possesses certain in vivo protective and preventative effects and can be used for the prevention and treatment of human metapneumovirus infection, showing great application potential.

The invention discloses an ERA / CRISPR-LFD dual detection system for simultaneously detecting avian metapneumoviruses B and C and application of the ERA / CRISPR-LFD dual detection system, and relates to the technical field of biology. The ERA / CRISPR-LFD dual detection system comprises an ERA amplification reaction primer probe group, crRNA (Complementary Ribonucleic Acid) and an ssDNA-FB Reporter, the ERA amplification reaction primer probe group comprises an upstream primer aMPV / B-F4, a downstream primer aMPV / B-R2, an upstream primer aMPV / C-F3, a downstream primer aMPV / C-R4 and a probe aMPV / C-R2 '''. A novel technical tool which is sensitive, specific, convenient, low in cost and high in stability is provided for on-site rapid typing detection of the avian metapneumoviruses B and C, and the kit has important practical application value and popularization prospect in early discovery, early prevention and control of related diseases of poultry and reduction of loss of the breeding industry.

Provided herein are vaccine composition comprising a chemically-modified messenger ribonucleic acid (mRNA) encoding a hMPV fusion (F) glycoprotein and / or a chemically-modified mRNA encoding a hRSV F glycoprotein formulated in a lipid nanoparticle, and related methods for inducing an antigen- specific immune response.

The invention discloses an anti-metapneumovirus M protein antibody and a derivative product and application thereof, the antibody is 7D4 or 5B8 and has high affinity and specificity to metapneumovirus M protein, and the derivative product comprises a detection reagent, a detection kit, a detection chip, a detection test strip and the like. The invention provides a new thought and strategy for early diagnosis or screening of metapneumovirus infection diseases.

An epitope-specific antigen-binding molecule specific for the human metapneumovirus (hMPV) fusion (F) protein is provided, which comprises a variable domain that contacts the hMPV F protein. The hMPV F protein-specific antigen-binding molecule comprises a heavy chain and a light chain. Also provided is a method for detecting an antibody specific for the hMPV F protein, comprising: a.) contacting a biological sample with the hMPV F protein; and b.) contacting the epitope-specific antigen-binding molecule with the hMPV F protein.

The application discloses a virus-like particle vaccine for preventing avian metapneumovirus type B and a preparation method thereof, and belongs to the field of veterinary biological products. The virus-like particle vaccine comprises a fusion protein with a coding gene sequence shown as SEQ ID NO: 2, and the fusion protein can self-assemble to form a virus-like particle. The application further discloses a preparation method and application of the virus-like particle vaccine for preventing avian metapneumovirus type B. The virus-like particle vaccine for preventing avian metapneumovirus type B has good immunization effect, small immunization dose, and can effectively prevent diseases caused by avian metapneumovirus type B. The preparation method is simple, can prepare antigen proteins of avian metapneumovirus type B in a large amount, has short time consumption, high expression amount, greatly reduces production cost, and is favorable for large-scale production.

The invention relates to the novel use of an immunogenic formulation containing the bacillus Calmette-Guérin (BCG) strain at a concentration between 10-10° bacteria, expressing at least one protein or immunogenic fragment of respiratory syncytial virus (RSV, Human Orthopneumovirus), in a pharmaceutically acceptable saline buffer solution because it serves to prepare a vaccine useful to prevent, treat, or attenuate human Metapneumovirus (hMPV) infections.

The present application relates to a human monoclonal neutralizing antibody targeting metapneumovirus F protein and application thereof, which comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: a complementarity determining region HCDR1 having an amino acid sequence as shown in SEQ ID NO:1, a complementarity determining region HCDR2 as shown in SEQ ID NO:2, and a complementarity determining region HCDR3 as shown in SEQ ID NO:3; and / or the light chain variable region comprises: a complementarity determining region LCDR1 having an amino acid sequence as shown in SEQ ID NO:4, a complementarity determining region LCDR2 as shown in AAS, and a complementarity determining region LCDR3 as shown in SEQ ID NO:5. The metapneumovirus monoclonal neutralizing antibody MV61 of the present application can specifically bind to metapneumovirus F antigen, has high affinity (about 0.18nM), high neutralization activity to different mutant strains of metapneumovirus, and excellent broad spectrum.

The invention discloses a metapneumovirus M protein antibody and application thereof. The amino acid sequences of the complementary determining regions of the heavy chain variable region and the light chain variable region of the metapneumovirus M protein antibody provided by the invention are clear and are respectively shown as SEQ ID NO: 1-8, and the metapneumovirus M protein antibody has relatively high affinity and specificity to the metapneumovirus M protein. The metapneumovirus M protein antibody disclosed by the invention can effectively avoid cross reaction and remarkably improve the accuracy and sensitivity of detection, is suitable for early antigen detection of metapneumovirus infection, provides a reliable technical means for screening of metapneumovirus and prevention and control of diseases, and has a wide clinical application prospect.

Antibodies that bind and can neutralize human metapneumovirus (HMPV) are described. The antibodies include antibody 4E11, 3B5, 4F11, and 7F8. Each of these antibodies and binding fragments thereof can be engineered into numerous formats for research, detection, and / or treatment of HMPV, individually and in various combinations.

This invention relates to a human monoclonal neutralizing antibody targeting the metapneumovirus F protein and its applications. It comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region includes amino acid sequences having complementarity-determining regions HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively; and / or, the light chain variable region includes amino acid sequences having complementarity-determining regions LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:4, AAS, and SEQ ID NO:5, respectively. The metapneumovirus monoclonal neutralizing antibody MV62 obtained by this invention can specifically bind to the metapneumovirus F antigen and has good broad-spectrum neutralizing activity and certain in vivo protective effects. It can efficiently neutralize representative metapneumovirus strains A1, B1, and A2b, and can be used for the prevention and treatment of human metapneumovirus infection, showing great promise for clinical application.

An in vitro method, composition and kit for determining the presence or absence of adenovirus, metapneumovirus, rhinovirus / enterovirus, and parainfluenza in a sample, including providing a reaction mixture containing the sample and at least one primer pair set. The primer pair set includes at least one primer pair A that specifically amplifies a portion of adenovirus genome; at least one primer pair B that specifically amplifies a portion of metapneumovirus genome; at least one primer pair C that specifically amplifies a portion of rhinovirus / enterovirus genome; and at least one primer pair D that specifically amplifies a portion of parainfluenza genome. The reaction mixture is subjected to reaction conditions suitable to amplify targeted nucleic acids, thereby generating at least one amplicon; wherein the presence or absence of at least one amplicon in the sample indicates the presence or absence of adenovirus, metapneumovirus, rhinovirus / enterovirus, and / or parainfluenza in the sample.

The invention relates to the technical field of biological products, in particular to a mutant of pre-fusion human metapneumovirus F protein and application of the mutant. The mutant is obtained by performing the following mutation on the basis of wild type pre-fusion human metapneumovirus F protein: amino acids at 86-112 sites or amino acids at 97-106 sites are replaced by flexible linkers. The application comprises the following steps: preparing a medicine for preventing or treating hMPV infection; preparing an immunogenic composition for inducing an organism to generate a neutralizing antibody aiming at the hMPV; preparing a reagent or a kit for detecting the hMPV antibody; screening or preparing an anti-hMPV antibody; and separating the hMPV specific B cells. The new pre-fusion human metapneumovirus F protein mutant is obtained through research and design, has remarkably better stability, expression level and affinity, can be used for hMPV diagnosis, antibody therapy and development of various vaccines, and has important application value.

The invention provides a PreF monoclonal antibody combination for metapneumovirus detection and application thereof.The PreF monoclonal antibody combination for metapneumovirus detection comprises a first antibody and a second antibody, the first antibody comprises a first light chain variable region and a first heavy chain variable region, and the second antibody comprises a second light chain variable region and a second heavy chain variable region; the second antibody comprises a second light chain variable region and a second heavy chain variable region; wherein the amino acid sequence of the first light chain variable region comprises VL-CDR1-3 as shown in SEQ ID NO: 1-3; the amino acid sequence of the first heavy chain variable region comprises VH-CDR1-3 as shown in SEQ ID NO: 4-6; the amino acid sequence of the second light chain variable region comprises VL-CDR1-3 as shown in SEQ ID NO: 7-9; and the amino acid sequence of the second heavy chain variable region comprises VH-CDR1-3 as shown in SEQ ID NO: 10-12. The monoclonal antibody combination can improve the sensitivity and accuracy of in-vitro detection.

This invention relates to a human monoclonal neutralizing antibody targeting the F protein of metapneumovirus and its applications. It comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region includes an amino acid sequence having a complementarity-determining region (CDR1) as shown in SEQ ID NO:1, a CDR2 as shown in SEQ ID NO:2, and a CDR3 as shown in SEQ ID NO:3, respectively; and / or, the light chain variable region includes an amino acid sequence having a CDR1 as shown in SEQ ID NO:4, a CDR2 as shown in KAS, and a CDR3 as shown in SEQ ID NO:5, respectively. The metapneumovirus monoclonal neutralizing antibody MV31 obtained by this invention exhibits strong binding affinity to metapneumovirus, good in vitro neutralization, high affinity, and in vivo protective activity; it provides a product for the detection and neutralization of metapneumovirus, and makes it possible to provide metapneumovirus products with in vivo protective activity, possessing the potential for treating and preventing infections of various metapneumovirus strains.

Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and / or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and / or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.

Provided are epitope-specific antigen-binding molecules specific to a human metapneumovirus (hMPV) Fusion (F) protein, in which the antigen-binding molecule comprises a variable domain that contacts the hMPV F protein. The antigen-binding molecule specific to an hMPV F protein comprises a heavy chain and a light chain. Further provided are methods for detecting antibodies specific to an hMPV F protein, a method comprising: a.) contacting a biological sample with an hMPV F protein; and b.) contacting an epitope-specific antigen-binding molecule with the hMPV F protein.

This invention discloses an antibody that specifically binds to the metapneumovirus M protein, along with related products and uses, including its amino acid sequence, encoding nucleic acid, expression vector, recombinant host cell, antibody derivative, and preparation method. Experiments have confirmed that the antibody exhibits high expression levels and purity in mammalian cells, binds to the target protein with high affinity and high specificity, and shows no cross-reactivity with various common respiratory viruses and the metapneumovirus N protein. It is suitable for developing diagnostic kits, test strips, chips, and other detection products for metapneumovirus infection, with broad application prospects.

The application provides a PreF monoclonal antibody combination for metapneumovirus detection and application thereof, the PreF monoclonal antibody combination for metapneumovirus detection comprises a first antibody and a second antibody, the first antibody comprises a first light chain variable region and a first heavy chain variable region, and the second antibody comprises a second light chain variable region and a second heavy chain variable region; wherein the amino acid sequence of the first light chain variable region comprises VL-CDR1-3 shown in SEQ ID NO:1-3; the amino acid sequence of the first heavy chain variable region comprises VH-CDR1-3 shown in SEQ ID NO:4-6; the amino acid sequence of the second light chain variable region comprises VL-CDR1-3 shown in SEQ ID NO:7-9; and the amino acid sequence of the second heavy chain variable region comprises VH-CDR1-3 shown in SEQ ID NO:10-12. The monoclonal antibody combination can improve the sensitivity and accuracy of in vitro detection.